文献速递关节外科

头孢他啶与妥布霉素联合万古霉素在抗生素间隔物治疗假体周围关节感染中的疗效相似且成本更低

Similar Efficacy and Lower Cost Associated With Ceftazidime Compared to Tobramycin Coupled With Vancomycin in Antibiotic Spacers in the Treatment of Periprosthetic Joint Infection.
PubMed 文献 · J Arthroplasty · 2024-04-16

本回顾性研究纳入2014至2022年243例因假体周围关节感染行I期翻修的患者,比较万古霉素联合妥布霉素(TV组127例)与万古霉素联合头孢他啶(CV组116例)的间隔物抗生素方案。I期内1年内感染复发率TV组9.8%对CV组7.8%(P=0.60),末次随访时分别为12.6%对8.6%(P=0.32),调整风险因素后结果不变。头孢他啶较妥布霉素每治疗100例预计节省68,550美元,作者认为数据支持继续研究和使用头孢他啶作为妥布霉素的替代。

要点

  • I期翻修后1年内感染复发率TV组9.8%对CV组7.8%,差异无统计学意义(P=0.60)。
  • 末次随访感染复发率TV组12.6%对CV组8.6%,差异无统计学意义(P=0.32)。
  • 头孢他啶较妥布霉素每治疗100例预计节省68,550美元。

核心结论

  • 在抗生素间隔物中以头孢他啶替代妥布霉素,假体周围关节感染根除成功率相似且成本更低。
  • 作者认为需要更大规模研究确认疗效和节省成本的结果,但数据支持继续研究和使用头孢他啶作为妥布霉素的替代。

研究设计与样本

  • 回顾性研究,纳入2014至2022年243例因假体周围关节感染行I期翻修的患者。
  • TV组127例,CV组116例;排除既往I期或两阶段翻修失败、术前急性肾损伤或终末期肾病患者。
  • 主要结局为需交换抗生素间隔物的复发性感染,研究效能足以检测10%的复发感染差异;采用卡方检验、t检验和多变量逻辑回归分析。

主要发现

  • I期内1年内感染复发率TV组9.8%对CV组7.8%(P=0.60)。
  • 末次随访感染复发率TV组12.6%对CV组8.6%(P=0.32)。
  • 调整潜在风险因素后结果未改变。
  • 头孢他啶较妥布霉素每治疗100例预计节省68,550美元。

临床怎么用

  • 作者认为数据支持继续研究和使用头孢他啶作为抗生素间隔物中妥布霉素的替代。

局限性

  • 作者指出需要更大规模研究确认疗效和节省成本的结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Vancomycin and tobramycin have traditionally been used in antibiotic spacers. In 2020, our institution replaced tobramycin with ceftazidime. We hypothesized that the use of ceftazidime/vancomycin (CV) in antibiotic spacers would not lead to an increase in treatment failure compared to tobramycin/vancomycin (TV). METHODS: From 2014 to 2022, we identified 243 patients who underwent a stage I revision for periprosthetic joint infection. The primary outcome was a recurrent infection requiring antibiotic spacer exchange. We were adequately powered to detect a 10% difference in recurrent infection. Patients who had a prior failed stage I or two-stage revision for infection, acute kidney injury prior to surgery, or end-stage renal disease were excluded. Given no other changes to our spacer constructs, we estimated cost differences attributable to the antibiotic change. Chi-square and t-tests were used to compare the two groups. Multivariable logistic regressions were utilized for the outcomes. RESULTS: The combination of TV was used in 127 patients; CV was used in 116 patients. Within one year of stage I, 9.8% of the TV group had a recurrence of infection versus 7.8% of the CV group (P = .60). By final follow-up, results were similar (12.6 versus 8.6%, respectively, P = .32). Adjusting for potential risk factors did not alter the results. Cost savings for ceftazidime versus tobramycin are estimated to be $68,550 per one hundred patients treated. CONCLUSIONS: Replacing tobramycin with ceftazidime in antibiotic spacers yielded similar periprosthetic joint infection eradication success at a lower cost. While larger studies are warranted to confirm these efficacy and cost-saving results, our data justifies the continued investigation and use of ceftazidime as an alternative to tobramycin in antibiotic spacers.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Lewis DC, Blackburn BE, Archibeck J, et al. Similar Efficacy and Lower Cost Associated With Ceftazidime Compared to Tobramycin Coupled With Vancomycin in Antibiotic Spacers in the Treatment of Periprosthetic Joint Infection. J Arthroplasty. 2024. PMID: 38631513. doi:10.1016/j.arth.2024.04.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。